小智港股覆盤 | 3月28日
今日，港股三大指數集體上漲。截止收盤，恆生指數漲1.31%，報21684點。國企指數漲1.54%，報7396點。恆生科技指數大漲2.62%，報4494點。市場約838只個股上漲，891只個股下跌。成交額突破1343.06億港幣，和昨天同期相比下跌8.99%。南下資金淨流出8.86億港幣。
盤面上，娛樂板塊集體拉昇。火巖控股漲超37%；比高集團漲超35%；寶新置地漲超27%；智傲控股漲超19%；ITP HOLDINGS漲超14%。寶新置地發盈喜，預期年度將取得重大除所得稅後溢利不少於3億港元。
電商板塊大漲靠前。美團-W漲超11%；京東健康漲超5%；阿裏巴巴-SW漲超3%；寶尊電商-SW漲超2%；同程旅行漲超1%。高盛：美團(3690.HK)業績勝預期，維持買入，予目標價300港元。
石油天然氣板塊漲幅較前。PERSTA漲超22%；中遠海能、MI能源、中國神華等多股漲超9%；飛尚無煙煤漲超8%。中遠海能擬爲全資子公司1億美元借款提供擔保；MI能源3月31日董事會考慮及通過全年業績；中國神華(601088.SH)發佈2021年業績，淨利潤502.69億元，同比增長28.3%，派末期股息2.54元/股。
海運板塊全線走低。勇利投資跌超15%；東方海外國際跌超10%；金輝集團、珠江船務等多股跌超3%；中遠海控跌超2%。勇利投資全年純利1,049萬美元，虧轉盈；東方海外國際全年股東應佔溢利71.28億美元，同比增長689.63%，擬派末期息2.61元；珠江船務去年股東應佔溢利4407.4萬港元，同比減少11.54%。
生物科技板塊走低。亞盛醫藥-B、聯康生物科技集團等多股跌超10%；創勝集團-B、再鼎醫藥-SB、榮昌生物-B等多股跌超8%。亞盛醫藥-B去年虧損7.82億元，研發開支增長36%；聯康生物科技集團發佈2021年業績，淨虧損1959.1萬港元，按年收窄72.5%；創勝集團-B發佈2021年業績，股東應佔虧損約17.16億元，同比擴大約4.42倍；興業證券：首予榮昌生物-B“審慎增持”評級，目標價85.41元港元。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
